1ST Source Bank Lowers Position in iShares Biotechnology ETF (NASDAQ:IBB)

1ST Source Bank cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 5.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,942 shares of the financial services provider’s stock after selling 835 shares during the period. 1ST Source Bank’s holdings in iShares Biotechnology ETF were worth $1,975,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF during the third quarter valued at $29,000. HHM Wealth Advisors LLC grew its holdings in iShares Biotechnology ETF by 200.0% during the fourth quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Bradley & Co. Private Wealth Management LLC bought a new position in iShares Biotechnology ETF during the fourth quarter valued at $32,000. Newbridge Financial Services Group Inc. bought a new position in shares of iShares Biotechnology ETF in the fourth quarter worth $33,000. Finally, Hager Investment Management Services LLC bought a new position in shares of iShares Biotechnology ETF in the fourth quarter worth $34,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $134.19 on Monday. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The business has a fifty day moving average price of $136.25 and a 200-day moving average price of $139.76. The firm has a market capitalization of $6.34 billion, a P/E ratio of 24.52 and a beta of 0.84.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.